Bioregnum channel feed – Endpoints News

Bioregnum channel feed

#ASCO22: A small China biotech player makes its debut at ASCO with promising data on its GPRC5D multiple myeloma drug

3 years ago

Presenting a live Endpoints News event: Managing a biotech in turbulent times

4 years ago

Working to right the ship, BridgeBio's Neil Kumar adds a $110M deal right on top of his cash haul from Bristol Myers

4 years ago

The collapse of SKYSCRAPER-01 is casting a pall over all the TIGITs. Are we in for another I/O fiasco?

4 years ago

That big R&D PARP win Clovis CEO Mahaffy touted a few weeks ago? The FDA isn't buying it

4 years ago

As Biogen hunts for a turnaround CEO, execs sketch out a hazy look at an uncertain new future

4 years ago

Gilead joins a lineup of Big Pharma partners betting big on TriNKETs, with a $300M cash ante to get started on a 5T4

4 years ago

Aviv Regev recruits a ‘purple unicorn’ for the top post in the computational pillar she’s building at Genentech

4 years ago

What did we learn from Biogen's CMS slapdown? Data rule

4 years ago

Clovis Oncology heralds a PARP victory in frontline ovarian cancer — does anyone really care much?

4 years ago

Sanofi R&D team accelerates blockbuster development efforts — while casting doubt on a heavyweight rival’s plans

4 years ago

As Gilead’s stock price gets blitzed after a series of pratfalls, why is Dan O’Day getting a small raise?

4 years ago

With its share price chewed to pieces, Nick Leschly's 2seventy scores $170M to help weather the storm

4 years ago

‘We would have no choice’: Biogen CEO Vounatsos isn’t about to let go of the budget axe — unless they break that losing streak

4 years ago

Bayer rushes support to Ukraine staff, helping with cash and housing as Russians attack major cities

4 years ago

US senator blasts J&J's Texas two-step bankruptcy as the pharma giant twists in the public spotlight

4 years ago

Mirati gets a standard review for its 'breakthrough' KRAS drug. And that is causing some hand wringing

4 years ago

Moderna’s once high-flying stock buckles under the weight of a biotech rout. Is it cheap yet?

4 years ago

The FDA approves Moderna's revolutionary new Covid-19 vaccine. What took so long?

4 years ago

Of course the market debacle will influence M&A, dealmaking. The pendulum is swinging back to buyers

4 years ago

'Altos was really a once-in-a-lifetime opportunity': Hal Barron reflects on his big move

4 years ago

Amicus gets hit with an 'unexpected' setback on a gene therapy tapped to lead $600M SPAC spinout

4 years ago

Billionaire BioNTech backers have been kicking the tires at Novartis' big generics arm — report

4 years ago

Promising to slim down and speed up, the ‘new’ J&J shakes up the executive committee ahead of the big split

4 years ago

First page Previous page 2 3 456 7 8 Next page Last page